{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T03:08:01Z","timestamp":1779246481575,"version":"3.51.4"},"reference-count":44,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2022,2,14]],"date-time":"2022-02-14T00:00:00Z","timestamp":1644796800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["eJHaem"],"published-print":{"date-parts":[[2022,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The multicenter, phase Ib CC\u2010122\u2010DLBCL\u2010001 dose\u2010expansion study (NCT02031419) explored the cereblon E3 ligase modulator (CELMoD) agent avadomide (CC\u2010122) plus rituximab in patients with relapsed\/refractory (R\/R) diffuse large B\u2010cell lymphoma (DLBCL) or follicular lymphoma (FL). Patients received avadomide 3\u00a0mg\/day 5 days on\/2 days off plus rituximab 375\u00a0mg\/m<jats:sup>2<\/jats:sup> on day 8 of cycle 1, day 1 of cycles 2 through 6, and day 1 of every third subsequent cycle for 2 years. Primary endpoints were safety and tolerability; preliminary efficacy was a secondary endpoint. A total of 68 patients were enrolled (DLBCL [<jats:italic>n<\/jats:italic>\u00a0=\u00a027], FL [<jats:italic>n<\/jats:italic>\u00a0=\u00a041; 31 lenalidomide\u2010na\u00efve, 10 lenalidomide\u2010treated]). Median age was 62 years (range, 33\u201384 years), and patients had received a median of 3 (range, 1\u20138) prior regimens. Among patients with DLBCL, 66.7% had primary refractory disease (partial response or less to initial therapy). Among patients with FL, 65.9% were rituximab\u2010refractory at study entry and 10.0% were lenalidomide\u2010refractory. The most common any\u2010grade avadomide\u2010related adverse events (AEs) were neutropenia (63.2%), infections\/infestations (23.5%), fatigue (22.1%), and diarrhea (19.1%). The most common grade\u00a03\/4 avadomide\u2010related AEs were neutropenia (55.9%) infections\/infestations (8.8%), and febrile neutropenia (7.4%). In patients with DLBCL, overall response rate (ORR) was 40.7% and median duration of response (mDOR) was 8.0 months. In patients with FL, ORR was 80.5% and mDOR was 27.6 months; response rates were similar in lenalidomide\u2010na\u00efve and \u2010treated patients. Avadomide plus rituximab was well tolerated, and preliminary antitumor activity was observed in patients with R\/R DLBCL and FL, including subgroups with typically poor outcomes. These results support further investigation of novel CELMoD agents in combination with rituximab in R\/R DLBCL and FL.<\/jats:p>","DOI":"10.1002\/jha2.394","type":"journal-article","created":{"date-parts":[[2022,2,15]],"date-time":"2022-02-15T04:27:56Z","timestamp":1644899276000},"page":"394-405","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Phase Ib study of avadomide (CC\u2010122) in combination with rituximab in patients with relapsed\/refractory diffuse large B\u2010cell lymphoma and follicular lymphoma"],"prefix":"10.1002","volume":"3","author":[{"given":"Loretta J.","family":"Nastoupil","sequence":"first","affiliation":[{"name":"Department of Lymphoma and Myeloma Division of Cancer Medicine MD Anderson Cancer Center The University of Texas  Houston Texas USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6117-320X","authenticated-orcid":false,"given":"John","family":"Kuruvilla","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology and Hematology Princess Margaret Cancer Centre University of Toronto  Toronto Ontario Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julio C.","family":"Chavez","sequence":"additional","affiliation":[{"name":"H. Lee Moffitt Cancer Center and Research Institute  Tampa Florida USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fontanet","family":"Bijou","sequence":"additional","affiliation":[{"name":"Institut Bergoni\u00e9  Bordeaux Cedex France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas E.","family":"Witzig","sequence":"additional","affiliation":[{"name":"Mayo Clinic  Rochester Minnesota USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Armando","family":"Santoro","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences Pieve Emanuele Milan Humanitas University Italy \u2010IRCCS Humanitas Research Hospital\u2010 Humanitas Cancer Center Rozzano  Milan Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian W.","family":"Flinn","sequence":"additional","affiliation":[{"name":"Sarah Cannon Research Institute  Nashville Tennessee USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carola","family":"Boccomini","sequence":"additional","affiliation":[{"name":"SC Ematologia ASOU Citt\u00e0 della Salute e della Scienza di Torino  Turin Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vaishalee P.","family":"Kenkre","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology University of Wisconsin  Madison Wisconsin USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Corradini","sequence":"additional","affiliation":[{"name":"IRCCS Istituto Nazionale dei Tumori University of Milano  Milano Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iris","family":"Isufi","sequence":"additional","affiliation":[{"name":"Yale Cancer Center  New Haven Connecticut USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David J.","family":"Andorsky","sequence":"additional","affiliation":[{"name":"Rocky Mountain Cancer Centers The US Oncology Network  Boulder Colorado USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonard M.","family":"Klein","sequence":"additional","affiliation":[{"name":"Illinois Cancer Specialists The US Oncology Network  Niles Illinois USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel R.","family":"Greenwald","sequence":"additional","affiliation":[{"name":"Cancer Center of Santa Barbara  Santa Barbara California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Randeep","family":"Sangha","sequence":"additional","affiliation":[{"name":"Cross Cancer Institute  Edmonton Alberta Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Shen","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb  Princeton New Jersey USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Hagner","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb  Princeton New Jersey USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Li","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb  Princeton New Jersey USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juergen","family":"Dobmeyer","sequence":"additional","affiliation":[{"name":"Centre for Innovation and Translational Research Europe (CITRE) Bristol\u2010Myers Squibb Company  Seville Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nian","family":"Gong","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb  Princeton New Jersey USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shailaja","family":"Uttamsingh","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb  Princeton New Jersey USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Pourdehnad","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb  Princeton New Jersey USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5221-353X","authenticated-orcid":false,"given":"Vincent","family":"Ribrag","sequence":"additional","affiliation":[{"name":"Institut Gustave Roussy  Villejuif France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2022,2,14]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)32407-2"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25460"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.151738"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2007.1.216"},{"key":"e_1_2_9_6_1","first-page":"5","article-title":"Epidemiology of non\u2010Hodgkin's lymphoma","volume":"9","author":"Thandra KC","year":"2021","journal-title":"Med Sci"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/35000501"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S34273"},{"key":"e_1_2_9_9_1","unstructured":"National Comprehensive Cancer Network.NCCN clinical practice guidelines in oncology (NCCN Guidelines) B\u2010cell lymphomas version 5.2021.https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/b\u2010cell.pdf. Accessed November 17 2021."},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-2818"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.28.1618"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-06-435842"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.7534"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-01011-z"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01113-2"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-02-628669"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2016.1231290"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V126.23.2704.2704"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12172"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(20)30208-8"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-1203"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/jha2.375"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/cas.14704"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.2403"},{"key":"e_1_2_9_25_1","first-page":"1008","article-title":"Leveraging gene expression subgroups to classify DLBCL patients and select for clinical benefit from a novel agent","volume":"135","author":"Risueno A","year":"2020","journal-title":"Blood"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1177\/2040620719841581"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/498342"},{"key":"e_1_2_9_28_1","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1182\/blood-2020-136834","article-title":"Primary analysis of Zuma\u20105: A phase 2 study of axicabtagene ciloleucel (axi\u2010cel) in patients with relapsed\/refractory (R\/R) indolent non\u2010Hodgkin lymphoma (iNHL)","volume":"136","author":"Jacobson C","year":"2020","journal-title":"Blood"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.75.4648"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804980"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30864-7"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31366-0"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2018891598"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019002395"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020001949"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3884"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.60.2383"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30441-1"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30225-4"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00010"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(20)30874-0"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.8020"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0282-y"},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(19)30089-4"},{"key":"e_1_2_9_45_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002183"}],"container-title":["eJHaem"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jha2.394","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jha2.394","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jha2.394","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T10:53:14Z","timestamp":1692874394000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jha2.394"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,14]]},"references-count":44,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["10.1002\/jha2.394"],"URL":"https:\/\/doi.org\/10.1002\/jha2.394","archive":["Portico"],"relation":{},"ISSN":["2688-6146","2688-6146"],"issn-type":[{"value":"2688-6146","type":"print"},{"value":"2688-6146","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,14]]},"assertion":[{"value":"2021-11-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-01-21","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-02-14","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}